Fadi Agour

As 2025 unfolds, the world of mass tort litigation shows no signs of slowing down. From pharmaceutical giants to tech behemoths, corporations across industries are facing an unprecedented wave of lawsuits that could reshape their futures. With judges issuing critical rulings, multidistrict litigation (MDL) panels consolidating cases, and bellwether trials on the horizon, the legal

Per- and polyfluoroalkyl substances (PFAS), often referred to as “forever chemicals,” have become a focal point of environmental and public health concerns in the United States. These synthetic chemicals, used for their water, heat, and grease-resistant properties, are now at the center of one of the largest mass tort litigations in U.S. history. With thousands

Ultra-processed foods (UPFs) have become a cornerstone of modern diets, but their convenience comes at a cost. As consumption of these foods has skyrocketed, so too have the alarming health complications linked to them, including obesity, diabetes, heart disease, and even certain cancers. This growing public health crisis has sparked a wave of litigation against

What is BioZorb? The BioZorb litigation is shaping up to be one of the most significant legal challenges of 2025, presenting a unique opportunity for plaintiff attorneys nationwide. This case revolves around a medical device designed to aid breast cancer patients but has since been linked to serious complications, sparking widespread litigation. As the legal

 A Growing Need for High-Quality Roundup Claimants As Roundup litigation continues to unfold, the volume of claims related to its potential link to Non-Hodgkin’s Lymphoma (NHL) continues to grow. This has led to an increasing demand for claimant leads that are not only legitimate but also meet specific criteria set by law firms. The challenge,

Oxbryta Litigation: A Deep Dive into the Legal Challenges and Industry Implications.   The recent recall of Oxbryta (voxelotor), a medication designed to treat sickle cell disease (SCD), has led to a wave of legal challenges that are reverberating throughout the pharmaceutical industry. Initially heralded as a breakthrough treatment for SCD, Oxbryta was approved by